Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • 1006-16: Assessment and Treatment of Transgender and Gender Expansive Youth

    Contains 5 Component(s), Includes Credits

    Presenter: Valerie Tobin, MS, PMHNP, PMHCNS-BC 1.25 pharmacology contact hours

    1006-16: Assessment and Treatment of Transgender and Gender Expansive Youth

    Enhance the knowledge and skill of PMH nurses to care for young persons who are transgender and gender expansive.

    Presenter: Valerie Tobin, MS, PMHNP, PMHCNS-BC

    Disclosures: The presenters and planners have no conflict of interest or commercial support to disclose.  Off-label uses will be discussed during this presentation.

    Session Length:  90 minutes

    Target Audience:  RN, APRN

    Session Objectives:
    Upon completion of this presentation, the participant will be able to:
    1. Describe gender identity.
    2. Recognize health risks for this population.
    3. Examine the Standards of Care developed by World Professional Association for Transgender Health.
    4. Develop a plan of care that differentiates between children and adolescents.
    5. Counsel a transgender patient about the risks and benefits of hormone treatments.

    Keywords: Transgender, LGBT, Adolescents, Children, Health Risks, Standards of Care

    Continuing Nursing Education
    1.25 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The American Psychiatric Nurses Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

    Originally Presented
    APNA 14th Annual Clinical Psychopharmacology Institute
    Hyatt Regency Baltimore on the Inner Harbor
    Friday, June 10, 2016
    3:30pm – 5:00pm

    Release Date: July 29, 2016
    The contact hours for this session expire: November 30, 2019

  • 1002-16: Pharmacologic Treatment of Schizophrenia: How Far Have We Come?

    Contains 5 Component(s), Includes Credits

    Presenter: John M. Kane, MD 1.5 contact hours

    1002-16: Pharmacologic Treatment of Schizophrenia: How Far Have We Come?

    This dynamic presentation will increase your knowledge of evidence based treatment decisions for persons diagnosed with Schizophrenia. Dr. Kane provides an overview of the comprehensive specialty care needed for first episode patients. He describes evidence based treatment methods that will assist in increased numbers of patients consistently taking their medications and living healthier lives.

    Presenter: John M. Kane, MD

    Disclosures: The speaker has indicated a significant financial interest or other affiliation with Honorarium or Consultant for Alkermes, Forum, Intra Cellular Therapies, Janssen, Lundbeck, Otsuka, Sunovion, Teva, Reviva. Shareholder in Medavante, Vanguard, LB Pharma.  Off-label uses will not be discussed during this presentation. The activity planners have no conflicts of interest to disclose.

    Session Length:  90 minutes

    Target Audience:  RN, APRN

    Session Objectives:
    Upon completion of this presentation, the participant will be able to:

    1. Increase understanding of comprehensive specialty care in first episode patients.
    2. Increase knowledge of issues surrounding adherence in medication-taking.
    3. Increase knowledge of long acting injectable and psychotics.
    4. Increase knowledge of clozapine indications and use.

    Keywords: Schizophrenia, Evidence based treatment, Medications, Long acting injectibles

    Continuing Nursing Education
    1.5 contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post test before the expiration date. You will have 5 tries to correctly answer the questions on the post test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The content of this CNE activity pertains to pharmacology.  Because states' requirements may vary, contact your Board of Nursing for more information.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

    Originally Presented
    APNA 14th Annual Clinical Psychopharmacology Institute
    Hyatt Regency Baltimore on the Inner Harbor
    Friday, June 10, 2016
    8:00am - 9:30am

    Release Date:  July 29, 2016
    The contact hours for this session expire: September 1, 2019

  • 1001-16: Benzodiazepines: Boon or Boondoggle and Counteraction

    Contains 5 Component(s), Includes Credits

    Presenter: Barbara Limandri, PhD, PMHNP, BC 2.0 contact hours

    1001-16: Benzodiazepines: Boon or Boondoggle and Counteraction

    An in-depth look at the pharmacokinetics and pharmacodynamics of benzodiazapines. Everything you need to develop knowledge and skill in assisting clients to withdraw from long-term use of benzodiazepines.

    Presenter: Barbara Limandri, PhD, PMHNP, BC

    Disclosures: The presenters and planners have no conflict of interest or commercial support to disclose.  Off-label uses will not be discussed during this presentation.

    Session Length:  1 Hour 45 minutes

    Target Audience:  RN, APRN

    Session Objectives:
    Upon completion of this presentation, the participant will be able to:
    1. Explain the issues of prescribing patterns of benzodiazepines in the United States.
    2. Review the mechanisms of action of benzodiazepines in relation to treatment outcomes.
    3. Discuss protocols for benzodiazepine withdrawal and discontinuation.

    Keywords: Benzodiazepines, Psychopharmacology, Protocols for Benzodiazepine Withdrawls

    Continuing Nursing Education
    2.0 contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post test before the expiration date. You will have 5 tries to correctly answer the questions on the post test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

    Originally Presented
    APNA 14th Annual Clinical Psychopharmacology Institute
    Hyatt Regency Baltimore on the Inner Harbor
    Thursday, June 9, 2016
    5:00pm – 7:00pm

    Release Date: July 29, 2016
    The contact hours for this session expire: September 1, 2019